The cloning and characterization of the extracellular calcium (Ca 2 þ )-sensing receptor (CaSR) from parathyroid glands, kidney, and several other cell types have demonstrated that Ca 2 þ ions can participate actively in their own regulation through receptor-mediated interactions. [1] [2] [3] In the parathyroid, CaSR controls peripheral Ca 2 þ homeostasis in the kidney, bone, and intestine by modulating the secretion of the parathyroid hormone (PTH) in response to low circulating levels of ionized Ca 2 þ . In other tissues, local CaSR activation triggers adaptive responses to microenvironmental variations in Ca 2 þ levels. CaSR belongs to family C of the superfamily of G protein-coupled receptors that also includes the receptors for the main neurotransmitters glutamate and g-aminobutyric acid. The CaSR consists of an extracellular domain of 612 amino acids, a 250 amino acid transmembrane domain of seven transmembrane helices, and a 200 amino acid carboxyterminal C-tail. 4 At the plasma membrane, CaSR resides as a disulfide-linked dimer. The presence of two or more binding sites for Ca 2 þ on each monomer results in a positive cooperativity that allows the receptor to respond over a narrow range of ligand concentrations, compared with other members of the same family. Mg 2 þ , Sr 2 þ , La 3 þ , Gd 3 þ , and highly positively charged organic compounds, such as polyamines (e.g. spermine), aminoglycoside antibiotics (e.g. neomycin), protamine, and polyarginine are also able to activate the receptor, even in the absence of extracellular Ca 2 þ . These polycationic agonists are termed type I agonists. Type 2 agonists, in contrast, require the presence of Ca 2 þ to activate CaSR and include L-amino acids and other organic compounds that act as allosteric activators of the receptor (the so-called calcimimetics).
Upon agonist binding, conformational changes in the transmembrane domain and intracellular domains trigger a number of intracellular signaling pathways. A characteristic signature of CaSR activation is the mobilization of intracellular Ca 2 þ via activation of phospholipase C. This leads to modulation of the activity of many channels and receptors, hormone secretion (e.g. PTH, calcitonin, growth hormone, adrenocorticotropic hormone, gastrin, insulin), and regulation of cellular activities such as proliferation, differentiation, apoptosis, and gene expression. 5, 6 Initially investigated in parathyroid glands and kidney, CaSR-mediated processes have been largely defined also in other tissues and are object of intense research. [7] [8] [9] [10] The study of activating and inactivating CaSR mutations in human disorders, [11] [12] [13] the development of mouse models for CaSR defects, 14, 15 and the identification of genetic polymorphisms in the CaSR gene 16, 17 have delineated a pivotal role for the receptor in divalent mineral ion (Ca 2 þ and Mg 2 þ ) homeostasis, phosphate (P i ) metabolism, and water reabsorption. This review aims to summarize our current knowledge about Ca 2 þ -and Mg 2 þ -sensing mechanisms, with special attention to the clinical implications of CaSRbased therapeutics on Ca 2 þ and Mg 2 þ handling. concentration within a narrow range (1.12-1.32 and 0.44-0.59 mmol/l, respectively) relies on the coordinated actions of the kidney, intestine, and bone under the hormonal and sensing control by the parathyroid glands ( Figure 1 ). In response to hypocalcemia, reduced binding of Ca 2 þ to CaSR in the parathyroid induces rapid PTH release from secretory granules, delays PTH degradation, and eventually results in parathyroid hyperplasia (Figure 2 (Figure 2 ). 20 In a hypercalcemic situation, CaSR inhibits PTH release and stimulates the secretion of calcitonin by the thyroid C cells. Calcitonin secretion represents a robust defense against hypercalcemia via decreased osteoclast-mediated bone resorption. 21 While hormonal regulation governing Ca 2 þ (re)absorption and mobilization from tissues has been extensively investigated, the regulatory mechanisms responsible for the systemic Mg 2 þ handling are still largely unknown. Generally, Mg 2 þ can modulate PTH secretion in a way similar to Ca 2 þ . [22] [23] [24] Increasing Mg 2 þ levels inhibits PTH release 25 and reduces agonist-stimulated cAMP accumulation in parathyroid. 26 Furthermore, diverse studies in either hemo-or peritoneal dialysis patients have reported an inverse relationship between plasma PTH and dialysate Mg 2 þ content. 27, 28 Nevertheless, in different expression systems, Ca 2 þ has been found to be a more potent stimulator of PTH secretion than Mg 2 þ . 23, 25, 29 However, in vivo, the concentration of Mg 2 þ in the local microenvironment within the parathyroid might differ significantly from its level in the blood.
The differences between the effects of Ca 2 þ and Mg 2 þ on the CaSR-mediated secretory responses might reside in their ability to bind to the receptor and/or in their involvement in the cell signaling cascade initiated by the CaSR. 30 A recent 
Kidney
Renal CaSR is an integral component of the homeostatic mechanisms that locally regulate mineral and water reabsorption in a PTH-independent manner. 32 In the kidney, CaSR is expressed widely along the nephron and exhibits segmentspecific cellular polarization (Figure 1 ).
In the proximal tubule of the nephron, CaSR is apical and its expression is modulated by 1,25(OH) 2 D 3 , 20,33 PTH, and dietary P i . 34 In this segment, CaSR controls PTH-dependent P i excretion and can affect 1,25(OH) 2 D 3 synthesis via the renal cytochrome P450 enzyme 25-hydroxyvitamin D 3 -1a-hydroxylase. 35, 36 The majority of Ca 2 þ and Mg 2 þ reabsorption occurs in the PT and in the thick ascending limb of Henle (TAL) via passive paracellular transport mediated by claudin-16 and claudin-19 ( Figure 1 ). 37 Claudin-16 and claudin-19 proteins form cation-permeable channels, and, when mutated, are a cause of familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC; OMIM 248250). 37 Interestingly, CaSR agonists (such as Ca 2 þ and Mg 2 þ ) can induce lysosomal degradation of claudin-16 in vitro. In the kidney, this would lead to Ca 2 þ and Mg 2 þ wasting in the pro-urine. 38 In TAL, the apical Na
À cotransporter NKCC2 and the renal outer medullary potassium channel renal outer medullary potassium (ROMK) generate a lumen-positive transepithelial potential difference, which drives cation reabsorption (largely Ca 2 þ and Mg 2 þ , but also Na þ ) through the paracellular route. 39 During hypercalcemia, activation of the basolateral CaSR inhibits ROMK and NKCC2, resulting in the dissipation of the driving force for paracellular transport, leading to Na þ , Ca 2 þ , and Mg 2 þ wasting. 40 Similarly, pharmacological inhibition of NKCC2 by furosemide completely abolishes the transepithelial voltage gradient across the TAL, and therefore drastically inhibits Ca 2 þ and Mg 2 þ reabsorption. Mutations in the genes for NKCC2, ROMK, CaSR, the chloride channel ClC-kb, and its accessory protein Barttin are the causative defects for different variants of the salt-wasting disorder known as Bartter's syndrome. [41] [42] [43] Although all of the Bartter's syndrome types are caused by inhibition of transport in the TAL due to a full or partial dissipation of the electrochemical gradient, there is a considerable and unexplained variability in the consequences of faulty divalent cation handling. 44 In the distal convoluted tubule (DCT), Ca 2 þ and Mg 2 þ reabsorption relies on active transcellular processes. The early DCT (DCT1) determines the final urinary Mg 2 þ concentration by reabsorbing 5-10% of the filtered Mg 2 þ via the epithelial transient receptor potential melastatin 6 (TRPM6) (Figure 1) . 45, 46 Recent studies demonstrated that CaSR activity reduces cell surface expression of the basolateral K þ channel Kir4.1. 47 This channel provides K þ ions to the NaK-ATPase, which maintains a local negative membrane potential essential for transcellular Mg 2 þ reabsorption in DCT1. 48, 49 Evidence for a crosstalk between CaSR and Kir4.1 suggests that activating mutations in the CaSR 11 as well as loss of function mutations in Kir4. 1 (refs. 48, 49) might affect renal Na þ reabsorption and cause Mg 2 þ wasting through the same mechanism. In the late DCT (DCT2) and connecting tubules, CaSR is likely to control the transcellular Ca 2 þ reabsorption via modulation of apical Ca 2 þ entry through TRPV5 and/or basolateral Ca 2 þ efflux mediated by the Na þ -Ca 2 þ exchanger (NCX1) and the Ca 2 þ -ATPase (PMCA1B). 50, 51 During hypocalcemic conditions, calciotropic hormones, including 1,25(OH) 2 D 3 and PTH, increase the expression and/or enhance the channel open probability of TRPV5. 52, 53 Experiments conducted in TRPV5 knockout (TRPV5 À/À ) mice elucidated an intriguing role of CaSR in the collecting duct. In this segment of the nephron, increased urinary Ca 2 þ levels activate the luminal CaSR, enhancing activity of the H þ -ATPase proton pump and downregulating the aquaporin 2 water channel. 54 The consequent decrease in urinary pH and polyuria protects the TRPV5 À/À mice from the risk of developing renal CaP i deposits. These adaptive mechanisms in a renal hypercalciuric mouse model indicate that renal CaSR and other local molecular actors could be novel therapeutic targets in preventing kidney stones in humans.
In conclusion, in vivo and in vitro studies showed that CaSR affects many molecular players involved in the paracellular and transcellular reabsorption of Ca 2 þ and Mg 2 þ in the kidney. Moreover, it provides crucial basolateral-and luminal-sensing mechanisms that integrate and balance water and divalent mineral losses.
Bone
The majority of body Ca 2 þ and Mg 2 þ is stored in the osseous tissue as hydroxyapatite, whitlockite, and amorphous CaP i crystals. Under physiological conditions, the maintenance of mineral stores in bone relies on the equilibrium between bone mineralization by osteoblasts and bone resorption by osteoclasts, the latter being a process that leads to mineral release into the extracellular fluids. Expression studies in bone reported CaSR transcripts in preosteoblasts and osteoblasts, as well as in osteoclast precursors and mature osteoclasts. 5, 55 Fluctuations in extracellular Ca 2 þ concentrations in vitro control osteoblast and osteoclast cell fate via pathways involving CaSR activation. 5, 56 The bone abnormalities observed in global CaSR knockout mice (CaSR À/À ) do not represent a conclusive evidence for the importance of the skeletal CaSR in vivo, as the hypercalcemia and hyperparathyroidism in these animals may be responsible for secondary effects on bone. 57, 58 Moreover, CaSR knockout is incomplete because of the gene targeting strategy that leads to the expression of a CaSR splice variant able to compensate for the loss of full-length CaSR in bone and cartilage of these animals. 59 Chang et al. 9 finally proved the critical role of the osteoblast CaSR in bone development, mineralization, and resorption, by generating a mouse model with an osteoblastspecific ablation of CaSR. These mice show profound bone defects that are independent of the calcitropic hormone axis and exclusively rely on local regulatory events that involve the skeletal CaSR. 9, 10 With respect to Ca 2 þ transport in bone, the TRP channels TRPV4, TRPV5, and TRPV6 are known to be involved in this process, as from in vitro studies and characterization of knockout mouse models. [60] [61] [62] At the ruffled border membrane of osteoclasts, the highly Ca 2 þ -selective channel TRPV5 participates to remove the mineralized bone matrix (Figure 1) , 62, 63 whereas TRPV4 regulates intracellular Ca 2 þ concentrations both in the osteoclast and osteoblast (Figure 1 ).
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A recent study demonstrated that TRPV6 is also expressed in the bone mainly at the luminal side of the osteoclast and in osteoblasts, but it is not crucial for bone mineralization in mice ( Figure 1 ). 61 Up to now, no regulatory mechanism on TRP channels by CaSR in bone has been described.
Although Mg 2 þ stores in bone are the best indicator of total body Mg 2 þ , the (patho)physiological role of Mg 2 þ in mineral mobilization remains unclear. Hypomagnesemia is generally associated with reduced bone mineral density in both rats and humans, 64 whereas hypermagnesemia is a risk factor for the development of adynamic bone disease, a condition characterized by abnormally low bone turnover. 65 In individuals whose renal function is not compromised, insufficient dietary Mg 2 þ intake has been linked to osteoporosis 66, 67 and the evidence for a loss of a magnesiotropic action of estrogens in Mg 2 þ homeostasis could be important in the development of postmenopausal osteoporosis. 68 Moreover, the use of proton-pump inhibitor drugs (PPIs) is associated with hypomagnesemia and increased risk of fractures. 69, 70 The mineral disturbances in chronic kidney disease (CKD) cause a spectrum of skeletal abnormalities, including osteitis fibrosa, osteomalacia, osteopenia, or osteoporosis, and adynamic bone disease. In studies on CKD patients, the differences in the management and complexity of mineral disturbances make it difficult to delineate a comprehensive overview of Mg 2 þ :Ca 2 þ ratio in bone, renal osteodystrophy, and total body Mg 2 þ balance. Before initiation of dialysis, bone biopsies of end-stage renal disease patients with different degrees of renal osteodystrophy revealed an increase in the Mg 2 þ :Ca 2 þ ratio with no increase in the total bone Mg 2 þ compared with healthy subjects. 71 Studies conducted after 2-year dialysis on a 0.65 mmol/l Mg 2 þ dialysate showed an increase in bone Mg 2 þ content. 72 The exact effect of Mg 2 þ before and after initiation of dialysis on bone mass, physical composition, and turnover is still unknown. The study of channels and transporters permitting Mg 2 þ to permeate bone cells and their crosstalk with divalent cationsensing mechanisms in bone will elucidate the direct actions of Mg 2 þ on skeletal integrity.
Intestine
In mammals, CaSR is expressed in both the luminal and basolateral membrane of epithelial cells along the entire length of the small and large intestine. Here, the receptor plays a role in cell growth and differentiation, fluid transport, and nutrient sensing. 73 Ca 2 þ and Mg 2 þ absorption in the intestine consists of both para-and transcellular pathways, with the paracellular transport being the predominant route in high dietary Ca 2 þ and Mg 2 þ conditions. 74 The majority of ingested Ca 2 þ is absorbed via a paracellular route in multiple segments of the small intestine, whereas active transcellular Ca 2 þ absorption mainly occurs in the duodenum via TRPV6. The majority of Mg 2 þ is absorbed from the small intestine via a paracellular route and to a lesser extent from the colon via transcellular transport. 75 Colonic absorption of Mg 2 þ likely involves TRPM6. 45 Overall, the local role of intestinal CaSR on the regulation of divalent cation homeostasis is still largely unknown. Interestingly, some activating mutations present a more severe phenotype similar to salt wasting syndrome (Gitelman's and Bartter's syndromes) with hypocalcemia, low PTH levels, renal Ca 2 þ wasting, nephrocalcinosis, hypomagnesemia, and hypermagnesuria. 11 Inactivating mutations of the CaSR, on the other hand, result in familial benign autosomal dominant hypocalciuric hypercalcemia (FHH, OMIM 145980), or its recessive form, neonatal severe hyperparathyroidism (OMIM 239200). 76 Patients affected with FHH or neonatal severe hyperparathyroidism exhibit hypercalcemia, hypermagnesemia, and normal to high levels of PTH. Mouse models for autosomal dominant hypocalcemic hypercalciuria and FHH resemble the human phenotype of the diseases. 14, 15 Mg 2 þ deficiency has been found to alter Ca 2 þ metabolism significantly in animals as well as in humans. 45, 46, 77 In particular, secondary hypocalcemia is commonly observed in patients with hypomagnesemia. Familial hypomagnesemia with secondary hypocalcemia (OMIM 602014) is an autosomal recessive disorder whose underlying cause is one of several mutations in the epithelial cation channel TRPM6. 45, 46 Unfortunately, homozygous deletion of TRPM6 is embryonically lethal in mice, and therefore limiting our understanding of the effect of Mg 2 þ homeostatic defects on Ca 2 þ metabolism. 78 However, heterozygous deletion of TRPM6 results in a mild hypomagnesemia with normocalcemia. 78 In these mice, In the parathyroid glands, hypomagnesemia is expected to increase PTH secretion. [22] [23] [24] Nevertheless, chronic Mg 2 þ deficiency can lead to the suppression of PTH release. [81] [82] [83] [84] [85] [86] Most probably, prolonged hypomagnesemia causes intracellular Mg 2 þ depletion that in turn is responsible for the constitutive activation of the CaSR signaling, block of PTH secretion, and ultimately secondary hypocalcemia due to decreased reabsorption of Ca 2 þ by the kidney. 30 Thus, the occurrence of either an acute or a chronic Mg 2 þ deficiency is likely on the basis of the discrepancies observed in the ability of this cation to modulate PTH release in the parathyroid glands.
INTERPLAY OF
Another hypothesis is that hypomagnesemia causes hypocalcemia due to the skeletal resistance to PTH. In vitro studies revealed that exposure to low extracellular Mg 2 þ concentrations causes less Ca 2 þ release from cultured fetal rat bone cells. 87 Similarly, bones from Mg 2 þ -depleted animals released less Ca 2 þ than control bones when exposed to PTH. 88 Nevertheless, a PTH-independent mode could also be involved. 89 The study of Mg 2 þ homeostasis in experimental models of Ca 2 þ -homeostatic disturbances will enable us to dissect the inter-regulatory mechanisms and the molecular players involved in the metabolism of these two cations. Disturbances of mineral metabolism, primarily hyperphosphatemia, are common during the course of CKD, and are classically accompanied by secondary hyperparathyroidism, bone disorders, and ectopic calcifications in soft tissues. Under physiological conditions, the bone-kidney-parathyroid axis controls P i and Ca 2 þ homeostasis via a regulatory loop that includes the fibroblast growth factor 23 (FGF23), Klotho, 1,25(OH) 2 D 3 , and PTH. Klotho was first identified as an aging suppressor. 92 It is mainly expressed in the kidney and parathyroid as single-span transmembrane protein, but is also secreted in blood and urine upon extracellular shedding. Secreted and intact Klotho exerts multiple biological actions in P i and Ca 2 þ metabolism. In the DCTs of the kidney, Klotho has a stimulatory effect on TRPV5 activity, 93 whereas in the parathyroid glands, it enhances the cell surface expression of the NaK-ATPase pump to generate the driving force for PTH secretion (Figure 2) . 94 Moreover, Klotho works as co-receptor for the phosphaturic hormone FGF23. 95, 96 Circulating P i and 1,25(OH) 2 D 3 positively regulate FGF23 release from bone. 97, 98 Binding of the secreted FGF23 to the Klotho/FGFR1 complex suppresses P i reabsorption and 1,25(OH) 2 D 3 synthesis, in the kidney, 99 whereas it decreases PTH secretion, in the parathyroid. 100 Klotho expression is induced by 1,25(OH) 2 D 3 101 and repressed by FGF23. 102 With the progression of CKD, Klotho levels decline, 103 causing FGF23 resistance, significant increase in FGF23 and PTH release, hypovitaminosis D, and hyperphosphatemia. Deletions of Klotho (Klotho À/À ) or FGF23 (FGF23 À/À ) in a mouse model lead to hyperphosphatemia, vascular calcification, and osteopenia, a phenotype that resembles the mineral and bone disease observed in CKD. 91, 92 On the other hand, Hu et al.
103
showed that transgenic mice overexpressing Klotho developed less severe vascular calcifications via a direct inhibition of P i uptake by vascular smooth muscle cells (VSMC) in combination with enhanced phosphaturia and improved glomerular filtration. The authors confirmed that Klotho supplementation might have therapeutic potential for CKD, as previously proposed by Nakatani et al. 104, 105 The current therapy for mineral and bone disorder in CKD mainly includes: use of 1,25(OH) 2 D 3 analogs, use of calcimimetic agents, control of P i via dietary restrictions, and use of oral P i binders, parathyroidectomy, and adjustment of dialysate mineral composition.
In addition to P i and Ca 2 þ imbalance, renal failure is the most common cause of hypermagnesemia. With the progression of CKD (glomerular filtration rate o30 ml/min), urinary Mg 2 þ excretion may be insufficient to balance intestinal Mg concentration commonly used in peritoneal dialysis solutions is 0.25-0.75 mmol/l and 0.75 mmol/l in hemodialysis, and is directly related to plasma Mg 2 þ concentrations. 27, 28 Recent studies reported that circulating Mg 2 þ levels inversely correlate with vascular calcification among end-stage renal disease patients 106 and with carotid intima-media thickness in hemodialysis patients. 107 As cardiovascular disease accounts for premature death in about 50% of dialysis patients, the monitoring of plasma Mg 2 þ together with Ca 2 þ and P i is crucial in CKD patients. In the general population, Mg 2 þ acts as a vasodilator and influences blood pressure, in part, by regulating peripheral vascular resistance and reactivity. 108 
Mg
2 þ deficiency is associated with endothelium dysfunction and atherosclerosis, whereas Mg 2 þ administration is linked to a decrease in blood pressure and significant improvement of endothelial function and VSMC response. 109 In patients affected by Gitelman's syndrome, characterized by hypocalciuria and hypomagnesemia, Mg 2 þ also reduced the recurrence of acute ectopic deposition of idiopathic CaP i crystals in the extracellular fluid. 110 Vascular calcification occurs in the vessel walls via a combination of extracellular and intracellular nanocrystal deposition, cellular differentiation towards an osteoblast-like phenotype, and cell apoptosis. 111 A recent study in a rat model of chronic renal failure showed that the calcimimetic AMG 641 could slow down the progression of vascular calcification. 112 Moreover, in vitro, calcimimetic R-568 inhibited mineral deposition in VSMC via local activation of CaSR. 113, 114 CaSR expression in the VSMC decreases, as the vessels calcify, following the progression of kidney failure. 115 One of the TRPC channels is probably responsible for Ca 2 þ entry in VSMC after CaSR activation. 116 As extracellular Mg 2 þ has been shown to negatively regulate calcification in VSMC through increased activity of the cation channel TRPM7, 117 118 In accordance with observations in uremic animals, the use of 1,25(OH) 2 D 3 analogs in CKD patients is associated with a decrease in intima-media thickness and coronary artery calcification. 119 Of note, the use of 1,25(OH) 2 D 3 analogs before the initiation of dialysis and in more advanced stage of CKD, when vitamin D resistance occurs, needs to be carefully monitored to prevent hypercalcemia, hyperphosphatemia, and metastatic calcifications.
It has been reported that vitamin D increases Mg 2 þ absorption in the jejunum. 120 Nevertheless, increased plasma Mg 2 þ levels due to therapy with vitamin D derivatives might not be sufficient to reduce PTH release in the parathyroid gland via CaSR activation and to prevent medial calcification in arteries.
As renal function deteriorates, the control of P i relies on the use of agents that bind ingested P i in the intestinal lumen to limit its absorption. 121 To this end, a variety of compounds with different limitations have been used, that is, aluminum hydroxide, Ca 2 þ -based compounds, Mg 2 þ salts, and nonCa 2 þ containing, non-aluminum containing P i binders. The use of Mg 2 þ salts in patients with renal failure before initiation of dialysis should be monitored to avoid the side effects of hypermagnesemia, but they can be safely used in combination with low Mg 2 þ dialysate. Mg 2 þ -based P i binders may contribute to lower PTH levels by a calcimimetic effect of Mg 2 þ on CaSR in the parathyroid glands and at the same time may improve cardiovascular outcomes via local CaSR modulation. It seems worthwhile to investigate whether Ca 2 þ -Mg 2 þ combined preparations represent a suitable compromise between effectiveness, low toxicity, low risk of hypercalcemia, and beneficial effects on the cardiovascular system. 122 As mineralized vessels and bone are both composed of mainly hydroxyapatite, whitlockite, and CaP i crystals, unravelling the differential ion transporters and sensors involved in vascular calcification and bone formation is essential for the development of target-specific Ca 2 þ -or Mg 2 þ -based therapies. 123, 125, 126 FHH1 is caused by mutations in the CaSR gene in more than 65% of patients, but the abnormalities underlying FHH2 and FHH3 are unknown. 127 Genes that reside in the associated candidate regions might encode for other Ca 2 þ sensors or proteins involved in processes upstream or downstream of CaSR activation. 128 The actions of Ca 2 þ could potentially also be mediated by one or more of the metabotropic glutamate receptors that sense Ca 2 þ (i.e. metabotropic glutamate receptors 1, 3, and 5). Interestingly, the extracellular domain of the G protein--coupled receptors CaSR, g-aminobutyric acid B and metabotropic glutamate receptors show a significant degree of sequence homology to the bacterial periplasmic nutrientbinding protein. One of the bacterial periplasmic nutrientbinding proteins, named PhoQ, acts as extracellular Mg 2 þ sensor. 129 PhoQ induces production of Mg 2 þ transport proteins in response to environmental Mg 2 þ deprivation in Salmonella. Although phylogenetics is a constant aid to Mg 2 þ research in eukaryotes, 130 so far none of the known eukaryotic proteins responsive to Mg 2 þ has been associated with divalent cation-sensing properties. 131 
CONCLUSIONS
Primary disturbances of the Ca 2 þ balance often display a concomitant disturbance of Mg 2 þ homeostasis and vice versa. Nevertheless, the cascades of cellular and molecular events that lead to the combined disturbances of these cations are mostly unknown. While the hormonal regulation governing Ca 2 þ reabsorption and mobilization from tissues has been largely investigated, a comprehensive regulatory mechanism describing systemic Mg 2 þ handling is still missing. So far, the epidermal growth factor 132 and estrogens 68 handling. Currently, calcimimetics that target the CaSR are successfully applied to control secondary hyperparathyroidism in CKD patients by lowering circulating PTH, P i , and Ca 2 þ levels, which in turn decreases vascular calcifications. Interestingly, extracellular Mg 2 þ negatively regulates vascular calcification and osteogenic differentiation in the presence of high P i and high Ca 2 þ concentrations. It has been hypothesized that calcimimetics, as well as Mg 2 þ , can activate local cation-sensing mechanisms that protect from ectopic mineralization processes. This observation evokes some interesting hypotheses that remain untested: (i) the existence of alternative CaSR isoforms involved in local sensing of divalent cations; (ii) the existence of an unknown Mg 2 þ sensor; and (iii) a role of intracellular Mg 2 þ in the regulation of CaSR-mediated events that lead to Ca 2 þ entry. In conclusion, the central role of the CaSR in the tight coupling of Ca 2 þ and Mg 2 þ metabolism suggests that the homeostasis of both these divalent cations has to be carefully monitored during the treatment of mineral disorders.
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